Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study.
about
Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosisAntibiotic adjuvant therapy for pulmonary infection in cystic fibrosisCurrent and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implicationsIgY antibodies in human nutrition for disease preventionBioactive Egg Components and InflammationVaccines for Pseudomonas aeruginosa: a long and winding roadAntiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposureProphylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice.Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in micePassive immune neutralization strategies for prevention and control of influenza A infections.Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.Pharmacological approaches to correcting the ion transport defect in cystic fibrosis.Growth inhibition of Staphylococcus aureus and escherichia coli strains by neutralizing IgY antibodies from ostrich egg yolk.Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications.Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.Precision medicine for the treatment of severe pneumonia in intensive care.Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophilsA trial with IgY chicken antibodies to eradicate faecal carriage of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamases.IgY: a key isotype in antibody evolution.Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.
P2860
Q24202222-7E3EE8B1-3FE0-40F5-9704-CC9E6367063FQ24234613-BA3E8DA4-CC3F-4124-AD58-61E0597A8942Q26747065-2586FD37-D703-46C5-BC63-30012210369EQ26781140-E61BEB5C-E686-4BB9-BE7A-59682E4B24AEQ26782731-8251BD0F-9DBE-4C1F-B072-C9E8B5938711Q26852817-53D802ED-BF7A-44EC-9C7B-50AA50C521B6Q27304441-B82A8957-A8CF-4187-8E8D-4C84B7197A87Q30388253-86A6D8B7-D8C5-4F4D-B773-CF37A7DA1869Q30403137-05CFDFF6-4D6E-42F0-95DB-3A631CA17BE4Q30413158-FA89393A-8401-4C89-AE37-F4EE76EFF6E3Q33836925-49753536-33EE-4BEA-A984-FA29B811D0EDQ35627639-0C83DAD1-F807-4A86-972D-F54DB48104BDQ37159941-BA7D3360-6CC2-41F3-8D86-F6598D40D794Q38323786-CAC63F00-90FF-4B1E-9E9A-5A228DE25076Q38697863-9ABE7BD2-B12C-49D6-975D-55E7883B9ED1Q38704065-7E7B30F8-4D34-4987-AA3D-8E4B9BE6E9F4Q40782287-A9100000-AF61-4879-BA3A-1E41F4061E6FQ40912929-E6C2ADD6-37A4-490D-9409-92061E22850DQ51097518-1193DD8B-9CDB-4415-B37C-91A01D2BE7DDQ52448914-8B6D29DB-35D2-4A5E-B4E1-6BE7334393C8
P2860
Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Oral administration of specifi ...... : a phase I feasibility study.
@en
Oral administration of specific yolk antibodies
@nl
type
label
Oral administration of specifi ...... : a phase I feasibility study.
@en
Oral administration of specific yolk antibodies
@nl
prefLabel
Oral administration of specifi ...... : a phase I feasibility study.
@en
Oral administration of specific yolk antibodies
@nl
P2093
P2860
P356
P1476
Oral administration of specifi ...... : a phase I feasibility study.
@en
P2093
Anders Larsson
David Carlander
Hanne Olesen
Hans Kollberg
Marie Johannesson
Per-Erik Wejåker
P2860
P304
P356
10.1002/PPUL.10290
P577
2003-06-01T00:00:00Z